In a recent study, researchers at York University and Sunnybrook Health Sciences Center in Toronto, Canada, developed an automated hierarchical deep learning model that can analyze digital pathology images of tumor biopsies taken before chemotherapy and accurately predict whether the tumor will have a complete pathological response.
In a significant development for the field of pathology, Medica is excited to introduce its pathologist-led reporting and scanning hub, situated in Runcorn, Cheshire.
The recent advancements in artificial intelligence (AI) have ignited excitement regarding its potential applications in the field of pathology. Evidence is accumulating that AI can make diagnoses more accurate, efficient, and standardized. However, industry professionals find themselves wondering: Is this rise of interest in AI merely a momentary hype, or will AI change the landscape of pathology practice?
Deep Bio, a leader in artificial intelligence (AI)-powered cancer diagnostics, announced today that it has been named to the Korea AI Startup 100 list. This prestigious list, representing a recognition of the nation’s most promising startups, marks the third consecutive year that Deep Bio has secured inclusion on this esteemed list.The Korea AI Startup 100 initiative seeks to recognize startups in Korea that are at the forefront of driving AI innovation. Candidate companies underwent rigorous evaluation by a panel of AI experts. The evaluation criteria, developed in partnership with the Korea Advanced Institute of Science and Technology (KAIST) and KT Economics & Management Research Institute, spanned quantitative factors such as market growth potential, corporate valuation, AI technology prowess, as well as qualitative aspects such as sustainability and corporate impact.“We are immensely honored to once again be recognized as a leading startup representing Korea. Our inclusion in the list for the third consecutive year is a validation of Deep Bio’s unwavering pursuit of innovation and the value we bring to the healthcare industry,” said Sun Woo Kim, founder and CEO of Deep Bio. “We remain committed to pioneering groundbreaking solutions that transform the landscape of digital pathology and cancer diagnostics.”Deep Bio pioneered AI-based pathology image analysis and cancer diagnosis research in Korea, leading the charge in the digital transformation of pathology. The company’s groundbreaking AI-based cancer diagnostic support software, DeepDx® Prostate, marks a significant milestone in the assessment of prostate cancer by empowering pathologists to make more precise and efficient diagnoses.On the global stage, Deep Bio is strategically expanding its footprint through partnerships with digital pathology platform providers across the United States, Europe, and India. The company also collaborates on groundbreaking research initiatives with esteemed institutions such as Stanford Medical School, Harvard Dana-Farber Cancer Institute, and other leading research organizations in the United States. Deep Bio consistently shares its innovative research findings through publication in renowned medical journals, including Cancers and npj Digital Medicine.For more information, please visit Deep Bio’s website or contact in**@***********kr.SOURCE: CISION PR Newswire
Pathology services form the backbone of the healthcare system, being involved in most patient interactions from primary diagnosis through to targeted treatment therapies. No other service plays such a crucial role throughout and beyond our lives – from before birth to after death.
Researchers in Carnegie Mellon University's School of Computer Science have developed a method that uses artificial intelligence to augment how cells are studied and could help scientists better understand and eventually treat disease.
Showcasing recent advances in the field of In Situ Hybridisation (ISH) and spatial transcriptomic methods, the Applications of In Situ Hybridisation and Spatial Profiling Methods...
Philips Business Leader and Head of Health Systems Solutions APAC Kim Hyo-shuk (first from left), Konyang University Hospital Director of Pathology Lee Choong-sik (fourth from left), and Konyang University Hospital Director Bae Jang-ho (fifth from left) pose among colleagues infront of the reently installed Philips digitalized pathology solution at the hospital. (Credit: Philips Korea)
A 1-year-old African Pygmy hedgehog was presented to exotics consultant, Madonna Livingstone for ovariohysterectomy due to a bloody vaginal discharge. However, during surgery, the uterus was grossly thickened, and the internal vagina was filled with blood. Dr Livingstone sent the uterus and ovaries to the pathology team at Nationwide Laboratories where Dr Marvin Firth (anatomic pathologist) examined the sections digitally. The ovaries showed occasional primary and secondary follicles, but most of the tissue was effaced by nests and islands of neoplastic cells that were often arranged in pseudorosettes and had classic, Call-Exner bodies within them which multifocally infiltrated adjacent ovarian tissue. The cellular morphology and architecture, along with these bodies led to a diagnosis of bilateral granulosa cell tumours (GCTs). The sections of the uterus showed proliferation of the endometrial mucosa with cystic degeneration and hyperplasia of endometrial glands, occasionally forming papillary projections into the uterine lumen. Glandular structures also extended down into the muscle layers (adenomyosis). Within these layers there was also noticeable inflammation. We believe that the GCTs have led to endometrial cystic degene
One of the most fundamentally critical elements of diagnostic histopathology is the ability to suspend all cellular activity in tissues and prevent degradation, and secondly, to process specimen in a manner that facilitates subsequent steps such as microtomy and staining.
